Its not just about numbers on the scale
Here is a breakdown of the latest blockbuster deal between Abbott and Novo Nordisk India, and what it means for the booming GLP-1 market
continued until disease progression, unacceptable toxicity, or up to 12 months (combination therapy) or up to 24 months (monotherapy) Other indication: select patients with Merkel cell carcinoma (Accelerated Approval) May 19, 2025 antihemophilic factor (recombinant), PEGylated-aucl (Jivi) Bayer
The phase 2 study in type 2 diabetes patients showed significant appetite reductions, but the overall weight loss was slightly lower than in the obesity-only trial (16.9% versus 24.2% at the highest doses over comparable timeframes)
This guide covers what happens when GH and IGF-1 rise beyond baseline, whether that carries meaningful cancer or metabolic risk, and what to actually monitor